The prevalence of obesity and diabetes is an increasing global problem, especially in
developed countries, and is referred to as the twin epidemics. As such, advanced treatment …

Peptides and proteins are widely used to treat a range of medical conditions; however, they
often have to be injected and their effects are short-lived. These shortcomings of the native …

Objective Obesity and its associated comorbidities represent a global health challenge with
a need for well-tolerated, effective, and mechanistically diverse pharmaceutical …

Non-natural amino acids are increasingly used as building blocks in the development of
peptide-based drugs as they expand the available chemical space to tailor function, half-life …

Cardiovascular diseases (CVD) remain the leading cause of death worldwide, and
pharmacotherapy of most of them is suboptimal. Thus, there is a clear unmet clinical need to …

Human serum albumin (hSA) is the major carrier protein for fatty acids (FAs) in plasma. Its
ability to bind multiple FA moieties with moderate to high affinity has inspired the use of FA …

Dysregulation of the CXCL12/CXCR4 axis is implicated in autoimmune, inflammatory, and
oncogenic diseases, positioning CXCR4 as a pivotal therapeutic target. We evaluated …

Peptide YY (PYY) is a gastrointestinal hormone consisting of 36 amino acids, that is
predominantly secreted by intestinal l-cells. Originally extracted from pig intestines, it …

Tirzepatide, a dual agonist of Glucose-Dependent Insulinotropic Polypeptide (GIP) and
Glucagon-Like Peptide 1 (GLP-1) receptors, improved glucose control and reduced body …

Disulfide constrained peptides (DCPs) show great potential as templates for drug discovery.
They are characterized by conserved cysteine residues that form intramolecular disulfide …